MBD2 and cholangiocarcinoma: Although primary CCA mice models with MBD2 overexpression exhibited cisplatin resistance, the combination of cisplatin and MM-102 could effectively eliminate tumors in the liver and decrease the Ki-67 rate compared with treatment with cisplatin or MM-102 alone.